Literature DB >> 428399

Chemical modification of taipoxin and the consequences for phospholipase activity, pathophysiology, and inhibition of high-affinity choline uptake.

J Fohlman, D Eaker, M J Dowdall, R Lüllmann-Rauch, T Sjödin, S Leander.   

Abstract

Treatment of taipoxin with p-bromophenacyl bromide resulted in modification of single histidine residues in the alpha and beta subunits. The modification decreased the neurotoxicity (lethality) 350-fold, but the inhibitory action on high-affinity choline transport was reduced only threefold. The phospholipase activity and Ca2+-association constants for taipoxin and its subunits were determined. A model for the neurotoxicity of taipoxin indicates the alpha subunit as the ultimate cause of the disruption of synaptic transmission.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 428399     DOI: 10.1111/j.1432-1033.1979.tb12922.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  3 in total

1.  Neurotoxicity and other pharmacological activities of the snake venom phospholipase A2 OS2: the N-terminal region is more important than enzymatic activity.

Authors:  Morgane Rouault; Lachlan D Rash; Pierre Escoubas; Eric Boilard; James Bollinger; Bruno Lomonte; Thomas Maurin; Carole Guillaume; Stéphane Canaan; Christiane Deregnaucourt; Joseph Schrével; Alain Doglio; José María Gutiérrez; Michel Lazdunski; Michael H Gelb; Gérard Lambeau
Journal:  Biochemistry       Date:  2006-05-09       Impact factor: 3.162

2.  Myotoxic activity of the crude venom and the principal neurotoxin, taipoxin, of the Australian taipan, Oxyuranus scutellatus.

Authors:  J B Harris; C A Maltin
Journal:  Br J Pharmacol       Date:  1982-05       Impact factor: 8.739

3.  Snake phospholipase A2 neurotoxins enter neurons, bind specifically to mitochondria, and open their transition pores.

Authors:  Michela Rigoni; Marco Paoli; Eva Milanesi; Paola Caccin; Andrea Rasola; Paolo Bernardi; Cesare Montecucco
Journal:  J Biol Chem       Date:  2008-09-22       Impact factor: 5.157

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.